Fig. 2

Responses of all 20 R/R B-ALL patients to CNCT19 CAR T cell therapy. In this single-center, open-label, prospective clinical trial, a total of 20 patients diagnosed with resistant or refractory CD19⁺ B cell acute lymphoblastic leukemia received an infusion of CNCT19 CAR T cells. Responses over time of each patient are presented as a swimmer plot